Cobra Venom Factor

Uniform pool of Cobra Venom Factor (CVF), a non-toxic complement activating reagent.

Product Specifications

Citations	27
Description	Uniform pool of Cobra Venom Factor (CVF), a non-toxic complement activating reagent.
Storage	Store at -70°C or below. Minimize freeze/thaw cycles.
Form	Frozen liquid (Phosphate Buffered Saline, pH 7.2 ± 0.2)
Concentration	1.0-1.2 mg/mL
Applications	See citations and technical data sheet for application info.

Technical Documents

Ordering Information

For Research Use Only. Not for use in diagnostic procedures.

Catalog Number	A600
Catalog Number (CE)	N/A
Size	1.0 mg
Price (USD)	$400.00
Price (EURO)	355,00 €

Request an Order

Contact us

US Phone	+1 (858) 552 1100
EU Phone	+353 (91) 412 474
US Email	contact-us@quidelortho.com
EU Email	contact-emea@quidelortho.com

Specifications
Citations
Certificate of Analysis

Specifications

Description	Uniform pool of Cobra Venom Factor (CVF), a non-toxic complement activating reagent.
Size	1.0 mg
Storage	Store at -70°C or below. Minimize freeze/thaw cycles.
Form	Frozen liquid (Phosphate Buffered Saline, pH 7.2 ± 0.2)
Concentration	1.0-1.2 mg/mL
Applications	See citations and technical data sheet for application info.
Purity	≥ 95% by SDS page
Source	Naja naja kaouthia (cobra)
Activity	8 units/mL to 20 units/mL for full complement conversion.
Molecular Weight	N/A
Background	Cobra Venom Factor (CVF), sometimes referred to as C3b(Cobra), is the non-toxic, complement activating component of cobra venom. Like naturally occurring C3b, CVF forms a complex with complement components Factor B and Factor D. This CVFBbD convertase is capable of activating C3 in a wide variety of species via the alternative complement pathway. Unlike the naturally occurring convertase (C3bBbD), the C3b(Cobra)BbD convertase is Factor H resistant and is therefore not inactivated by Factor I or CR1. Given appropriate incubation time, CVF will convert nearly 100% of the C3 to C3 end products. Unlike CVF purified from the Naja naja haje species, CVF from Naja naja kaouthia activates the terminal pathway directly by forming a C5 convertase. This depletes C5 in a manner analogous to that described above for C3. Levels of iC3b, C3a, SC5b-9, C5a and the Factor B cleavage product Bb are all extremely high in CVF treated sera.

Citations

Title	Year	Applications	Sample Species	Sample	Sample Details
Antibodies and complement are key drivers of thrombosis	2024	Complement depletion assay	Mouse	Protein Injection	Venous thromboembolism
Increased Complement Activation and Decreased ADAMTS13 Activity Are Associated with Genetic Susceptibility in Patients with Preeclampsia/HELLP Syndrome Compared to Healthy Pregnancies: An Observational Case-Controlled Study	2024	Complement depletion assay	Human	Serum	COVID-19
Up to 9-day survival and control of thrombocytopenia following alpha1,3-galactosyl transferase knockout swine liver xenotransplantation in baboons	2012	Complement Depletion Assay	Baboon	Protein Injection
Chimeric 2C10R4 anti-CD40 antibody therapy is critical for long-term survival of GTKO.hCD46.hTBM pig-to-primate cardiac xenograft	2016	Complement Depletion Assay	Baboon	Protein Injection
Graphene Oxide Nanosheets for Localized Hyperthermia-Physicochemical Characterization, Biocompatibility, and Induction of Tumor Cell Death.	2020	Complement Activation Assay	Human	Plasma
Interaction of colloidal gold nanoparticles with human blood: effects on particle size and analysis of plasma protein binding profiles	2009	Complement Activation Assay	Human	Plasma	Gold Nanoparticles incubated
Zwitterionic chitosan derivatives for pH-sensitive stealth coating	2010	Complement Activation Assay	Human	Plasma
Nanoparticles size-dependently initiate self-limiting NETosis-driven inflammation	2016	Complement Activation Assay	Human	Serum
Soluble MAC is primarily released from MAC-resistant bacteria that potently convert complement component C5.	2022	Complement Depletion Assay	Human	Serum
Molecular response of chorioretinal endothelial cells to complement injury: implications for macular degeneration	2016	Complement Depletion Assay	Human	Serum
Discovery of monoclonal antibodies cross-reactive to novel subserotypes of K. pneumoniae O3	2017	Complement Depletion Assay	Human	Serum
A Conformational Change of Complement C5 Is Required for Thrombin-Mediated Cleavage, Revealed by a Novel Ex Vivo Human Whole Blood Model Preserving Full Thrombin Activity.	2021	WB	Human	Purified protein
The role of innate immune responses in the outcome of interspecies competition for colonization of mucosal surfaces	2005	Complement Depletion Assay	Mouse	Protein Injection
Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcgammaRI, FcgammaRIII, and FcgammaRIV	2008	Complement Depletion Assay	Mouse	Protein Injection
Natural antibody to conserved targets of Haemophilus influenzae limits colonization of the murine nasopharynx	2009	Complement Depletion Assay	Mouse	Protein Injection
Complement promotes the development of inflammatory T-helper 17 cells through synergistic interaction with Toll-like receptor signaling and interleukin-6 production	2009	Complement Depletion Assay	Mouse	Protein Injection
SIGN-R1, a C-type lectin, enhances apoptotic cell clearance through the complement deposition pathway by interacting with C1q in the spleen	2013	Complement Depletion Assay	Mouse	Protein Injection
Cutting edge: the NLRP3 inflammasome links complement-mediated inflammation and IL-1β release	2013	Complement Depletion Assay	Mouse	Protein Injection
Yersinia pseudotuberculosis uses Ail and YadA to circumvent neutrophils by directing Yop translocation during lung infection	2014	Complement Depletion Assay	Mouse	Protein Injection
C3 dysregulation due to factor H deficiency is mannan-binding lectin-associated serine proteases (MASP)-1 and MASP-3 independent in vivo	2014	Complement Depletion Assay	Mouse	Protein Injection
Efficiency of conditionally attenuated Salmonella enterica serovar Typhimurium in bacterium-mediated tumor therapy	2015	Complement Depletion Assay	Mouse	Protein Injection
Endotoxin neutralization by an O-antigen specific monoclonal antibody: A potential novel therapeutic approach against Klebsiella pneumoniae ST258	2017	Complement Depletion Assay	Mouse	Protein Injection
Complement Depletion Improves Human Red Blood Cell Reconstitution in Immunodeficient Mice	2017	Complement Depletion Assay	Mouse	Serum
Intravital immunofluorescence for visualizing the microcirculatory and immune microenvironments in the mouse ear dermis	2013	IF	Mouse	Ear dermis Tissue
Treatment with Cobra Venom Factor Decreases Ischemic Tissue Damage in Mice	2024	Complement depletion assay	Mouse	Serum	Tissue ischemia
No expression of porcine endogenous retrovirus after pig to monkey xenotransplantation	2014	Complement Depletion Assay	Porcine	Protein Injection
Complement inhibition prevents oncolytic vaccinia virus neutralization in immune humans and cynomolgus macaques	2015	Complement Depletion Assay	Rat	Protein Injection
Complement-independent retinal pathology produced by intravitreal injection of neuromyelitis optica immunoglobulin G	2016	Complement Depletion Assay	Rat	Protein Injection
Complement inhibition enables tumor delivery of LCMV glycoprotein pseudotyped viruses in the presence of antiviral antibodies	2016	Complement Depletion Assay	Rat	Protein Injection

Certificate of Analysis

Showing results for

No results found for